Key result
Darbepoetin alfa is a biologically modified erythropoietic protein that increases hemoglobin in adults, with pharmacokinetic and phase II studies currently ongoing in preterm infants and neonates.
Darbepoetin alfa is a biologically modified erythropoietic protein with a longer half-life that is currently being evaluated for the treatment of hyporegenerative anemias in neonates.
Darbepoetin alfa remains investigational for neonatal anemia; leaves open its efficacy and safety pending ongoing pharmacokinetic and phase II trials.
Many hyporegenerative anemias in adults result from insufficient erythropoietin production, and the administration of recombinant human erythropoietin effectively stimulates red cell production. A biologically modified erythropoietic protein with a significantly longer half-life, darbepoetin alfa (Aranesp®), was developed by Amgen to allow for less frequent dosing. Studies in adults showed that darbepoetin alfa increased hemoglobin using once weekly to once every three week dosing. Studies evaluating the effectiveness of darbepoetin in treating other hyporegenerative anemias in adults and children are ongoing. Single dose pharmacokinetics have been determined in preterm infants, and phase II neonatal studies are in progress.
No takes yet. Share an insight, caveat, or question.
Ohls et al. (2009) conducted a review in Hyporegenerative anemias. Darbepoetin alfa was evaluated. Darbepoetin alfa is a biologically modified erythropoietic protein that increases hemoglobin in adults, with pharmacokinetic and phase II studies currently ongoing in preterm infants and neonates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: